’s founding team (L to R): CTO Roy Nevo, scientific founder Avi Schroeder, CEO Yogev Debbi, and scientific co-founder Kira Radinsky

Ex­clu­sive: An­dreessen Horowitz-backed start­up is us­ing AI to de­sign lipid nanopar­ti­cles that go be­yond the liv­er

One of the biggest chal­lenges fac­ing ge­net­ic med­i­cines is get­ting them to the right part of the body. Lit­tle balls of fat called lipid nanopar­ti­cles used to car­ry mR­NA can be in­ject­ed in­to the arm for vac­cines or in­fused in­to the blood to shut­tle ge­net­ic med­i­cines to the liv­er. But de­liv­er­ing the mol­e­cules to oth­er cells or or­gans re­mains a chal­lenge.

A new start­up called hopes to change that, End­points News has learned. Based in Tel Aviv, Is­rael, has raised $19.5 mil­lion in seed fi­nanc­ing from An­dreessen Horowitz Bio + Health (a16z), Base4 Cap­i­tal, NFX, Li­on­Bird and Tech­nion — Is­rael In­sti­tute of Tech­nol­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.